SAPPHIRE: Phase III Study of Sitravatinib Plus Nivolumab Versus Docetaxel in Advanced Non-Squamous Non-Small Cell Lung Cancer

BACKGROUND: Checkpoint inhibitor (CPI) therapy revolutionized treatment for advanced non-small cell lung cancer (NSCLC); however, most patients progress due to primary or acquired resistance. Sitravatinib is a receptor tyrosine kinase inhibitor that can shift the immunosuppressive tumor microenvironment towards an immunostimulatory state. Combining sitravatinib with nivolumab (sitra+nivo) may potentially overcome initial CPI resistance. PATIENTS AND METHODS: In the phase III SAPPHIRE study, patients with advanced non-oncogenic driven, non-squamous NSCLC who initially benefited from (

• Borghaei, H.
• de Marinis, F.
• Dumoulin, D.
• Reynolds, C.
• Theelen, Wsme
• Percent, I.
• Calderon, V. G.
• Johnson, M. L.
• Madroszyk-Flandin, A.
• Garon, E. B.
• He, K.
• Planchard, D.
• Reck, M.
• Popat, S.
• Herbst, R. S.
• Leal, T. A.
• Shazer, R. L.
• Yan, X.
• Harrigan, R.
• Peters, S.